Markus R Meyer - JoVE Visualize

Showing results (101-110 of 261) with videos related to

Pageof 27

Sort By:

Metabolites|December 30, 2020

Liquid Chromatography-High-Resolution Mass Spectrometry-Based In Vitro Toxicometabolomics of the Synthetic Cathinones 4-MPD and 4-MEAP in Pooled Human Liver MicrosomesSascha K Manier, Florian Schwermer, Lea Wagmann, et al.

Talanta|September 18, 2017

Development of a quantitative approach in blood plasma for low-dosed hallucinogens and opioids using LC-high resolution mass spectrometryAchim T Caspar, Andreas B Kollas, Hans H Maurer, et al.

Molecules (Basel, Switzerland)|April 3, 2021

Assessing Adherence to Antihypertensive Medication by Means of Dose-Dependent Reference Plasma Concentration Ranges and Ultra-High Performance Liquid Chromatography-Ion Trap Mass Spectrometry AnalysisLea Wagmann, Aline C Vollmer, Lucas Lauder, et al.

Journal of Mass Spectrometry : JMS|June 10, 2011

Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urineAndrea E Schwaninger, Markus R Meyer, Marilyn A Huestis, et al.

Metabolites|June 26, 2024

Characterization and Metabolism of Drug Products Containing the Cocaine-Like New Psychoactive Substances Indatraline and TroparilSascha K Manier, Paula Mumber, Josef Zapp, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 27, 2007

Identification of cytochrome P450 enzymes involved in the metabolism of the new designer drug 4'-methyl-alpha-pyrrolidinobutyrophenoneFrank T Peters, Markus R Meyer, Denis S Theobald, et al.

Analytical and Bioanalytical Chemistry|November 1, 2022

Closing the gap - development of an analytical methodology using volumetric absorptive microsampling of finger prick blood followed by LC-HRMS/MS for adherence monitoring of antihypertensive drugsCathy M Jacobs, Michael Kunz, Felix Mahfoud, et al.

Drug Testing and Analysis|January 27, 2016

Toxicokinetics of new psychoactive substances: plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212-2 studied using in vitro tools and LC-HR-MS/MSMarie Mardal, Emma Gracia-Lor, Svenja Leibnitz, et al.

Analytical and Bioanalytical Chemistry|December 10, 2016

Biotransformation and detectability of the new psychoactive substances N,N-diallyltryptamine (DALT) derivatives 5-fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT in urine using GC-MS, LC-MS<sup>n</sup>, and LC-HR-MS/MSJulian A Michely, Simon D Brandt, Markus R Meyer, et al.

Archives of Toxicology|August 28, 2021

Cytotoxicity, metabolism, and isozyme mapping of the synthetic cannabinoids JWH-200, A-796260, and 5F-EMB-PINACA studied by means of in vitro systemsTanja M Gampfer, Lea Wagmann, Anouar Belkacemi, et al.

Pageof 27

Showing results (101-110 of 261) with videos related to

Sort By:

Pageof 27

Metabolites|December 30, 2020

Liquid Chromatography-High-Resolution Mass Spectrometry-Based In Vitro Toxicometabolomics of the Synthetic Cathinones 4-MPD and 4-MEAP in Pooled Human Liver MicrosomesSascha K Manier, Florian Schwermer, Lea Wagmann, et al.

Talanta|September 18, 2017

Development of a quantitative approach in blood plasma for low-dosed hallucinogens and opioids using LC-high resolution mass spectrometryAchim T Caspar, Andreas B Kollas, Hans H Maurer, et al.

Molecules (Basel, Switzerland)|April 3, 2021

Assessing Adherence to Antihypertensive Medication by Means of Dose-Dependent Reference Plasma Concentration Ranges and Ultra-High Performance Liquid Chromatography-Ion Trap Mass Spectrometry AnalysisLea Wagmann, Aline C Vollmer, Lucas Lauder, et al.

Journal of Mass Spectrometry : JMS|June 10, 2011

Development and validation of LC-HRMS and GC-NICI-MS methods for stereoselective determination of MDMA and its phase I and II metabolites in human urineAndrea E Schwaninger, Markus R Meyer, Marilyn A Huestis, et al.

Metabolites|June 26, 2024

Characterization and Metabolism of Drug Products Containing the Cocaine-Like New Psychoactive Substances Indatraline and TroparilSascha K Manier, Paula Mumber, Josef Zapp, et al.

Drug Metabolism and Disposition: the Biological Fate of Chemicals|October 27, 2007

Identification of cytochrome P450 enzymes involved in the metabolism of the new designer drug 4'-methyl-alpha-pyrrolidinobutyrophenoneFrank T Peters, Markus R Meyer, Denis S Theobald, et al.

Analytical and Bioanalytical Chemistry|November 1, 2022

Closing the gap - development of an analytical methodology using volumetric absorptive microsampling of finger prick blood followed by LC-HRMS/MS for adherence monitoring of antihypertensive drugsCathy M Jacobs, Michael Kunz, Felix Mahfoud, et al.

Drug Testing and Analysis|January 27, 2016

Toxicokinetics of new psychoactive substances: plasma protein binding, metabolic stability, and human phase I metabolism of the synthetic cannabinoid WIN 55,212-2 studied using in vitro tools and LC-HR-MS/MSMarie Mardal, Emma Gracia-Lor, Svenja Leibnitz, et al.

Analytical and Bioanalytical Chemistry|December 10, 2016

Biotransformation and detectability of the new psychoactive substances N,N-diallyltryptamine (DALT) derivatives 5-fluoro-DALT, 7-methyl-DALT, and 5,6-methylenedioxy-DALT in urine using GC-MS, LC-MS<sup>n</sup>, and LC-HR-MS/MSJulian A Michely, Simon D Brandt, Markus R Meyer, et al.

Archives of Toxicology|August 28, 2021

Cytotoxicity, metabolism, and isozyme mapping of the synthetic cannabinoids JWH-200, A-796260, and 5F-EMB-PINACA studied by means of in vitro systemsTanja M Gampfer, Lea Wagmann, Anouar Belkacemi, et al.

Pageof 27